BPG is committed to discovery and dissemination of knowledge
Cited by in CrossRef
For: Cao WT, Huang R, Liu S, Fan YH, Xu MS, Xu Y, Ni H. Infliximab trough level combined with inflammatory biomarkers predict long-term endoscopic outcomes in Crohn’s disease under infliximab therapy. World J Gastroenterol 2022; 28(23): 2582-2596 [PMID: 35949356 DOI: 10.3748/wjg.v28.i23.2582]
URL: https://www.wjgnet.com/1007-9327/full/v28/i23/2582.htm
Number Citing Articles
1
Yun Qiu, Shixian Hu, Kang Chao, Lingjie Huang, Zicheng Huang, Ren Mao, Fengyuan Su, Chuhan Zhang, Xiaoqing Lin, Qian Cao, Xiang Gao, Minhu Chen. Developing a Machine-Learning Prediction Model for Infliximab Response in Crohn’s Disease: Integrating Clinical Characteristics and Longitudinal Laboratory TrendsInflammatory Bowel Diseases 2024;  doi: 10.1093/ibd/izae176
2
Junya Song, Huihui Zhang, Huihua Zhang, Ximing Xu, Xiaohua Liang, Yongfang Liu, Xiaomei Song, Hong Guo, Xue Zhan, Jinlin Song, Xiaoqin Zhou. The role of proactive therapeutic drug monitoring in guiding infliximab therapeutic optimization in pediatric patients with Crohn's disease: A retrospective studyPediatric Discovery 2024;  doi: 10.1002/pdi3.96
3
Sarah Bencardino, Ferdinando D’Amico, Alessandra Zilli, Tommaso Lorenzo Parigi, Mariangela Allocca, Gionata Fiorino, Silvio Danese, Federica Furfaro. Fecal, Blood, and Urinary Biomarkers in Inflammatory Bowel DiseasesJournal of Translational Gastroenterology 2024; 2(2): 61 doi: 10.14218/JTG.2024.00017